Related references
Note: Only part of the references are listed.Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
Harshal R. Patil et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Impact of Hypoglycemia Associated With Antihyperglycemic Medications on Vascular Risks in Veterans With Type 2 Diabetes
Yingnan Zhao et al.
DIABETES CARE (2012)
The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis
K. M. Pantalone et al.
DIABETIC MEDICINE (2012)
Medication Adherence in Type 2 Diabetes: The ENTRED Study 2007, a French Population-Based Study
Michel Tiv et al.
PLOS ONE (2012)
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
Thomas Karagiannis et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Comparisons of Persistence and Durability Among Three Oral Antidiabetic Therapies Using Electronic Prescription-Fill Data: The Impact of Adherence Requirements and Stockpiling
R. A. Greevy et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Kathleen R. Richard et al.
CLINICAL THERAPEUTICS (2011)
DPP-4 Inhibitors Impact on glycemic control and cardiovascular risk factors
Dror Dicker
DIABETES CARE (2011)
Behandlung des Diabetes mellitus Typ 2
S. Matthaei et al.
Diabetologie und Stoffwechsel (2011)
Hypoglycaemia: current management and controversies
Pratik Choudhary et al.
POSTGRADUATE MEDICAL JOURNAL (2011)
The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy A retrospective analysis
Kevin M. Pantalone et al.
DIABETES CARE (2010)
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
M. Ligueros-Saylan et al.
DIABETES OBESITY & METABOLISM (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients-A Population-Based Study
Jean-Pierre Gregoire et al.
VALUE IN HEALTH (2010)
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
Manfredi Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Ioanna Tzoulaki et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review
J. A. Cramer et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
HD Quan et al.
MEDICAL CARE (2005)
Share Paper
